Want to see AU:EZZ full AI Analyst Report?
Top Page
EZZ Life Science Holdings Ltd.
(Sydney:EZZ)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.32
▼(-50.31% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by the FY2026 operational setback and cash burn (losses, margin compression, and negative operating/free cash flow), alongside clearly bearish technical trends (price below all major moving averages and negative MACD). The strong low-debt balance sheet provides resilience, and the high dividend yield supports the valuation component, but sustainability risk remains given the latest loss and negative cash flow.
Positive Factors
Low financial leverage
Minimal debt reduces interest and refinancing pressure, giving EZZ greater flexibility during operating volatility. A sizable equity base can also support investment in products, distribution, or recovery initiatives without relying heavily on additional borrowing, provided profitability is restored.
Negative Factors
Sharp revenue and earnings deterioration
The sharp revenue contraction and shift into losses show that recent demand, product mix, or execution has weakened materially. Unless growth returns, lower scale will limit operating leverage, reduce reinvestment capacity, and make the prior record of profitability less representative of near-term earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Minimal debt reduces interest and refinancing pressure, giving EZZ greater flexibility during operating volatility. A sizable equity base can also support investment in products, distribution, or recovery initiatives without relying heavily on additional borrowing, provided profitability is restored.
Read all positive factors
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$15.05M
Dividend Yield12.55%
Average Volume (3M)17.42K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-30.79%
EPS Growth-177.68%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding47,043,200
10 Day Avg. Volume20,004
30 Day Avg. Volume17,419
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.70
Price to Sales (P/S)0.37
P/FCF Ratio-1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)AU$105.10M
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
Company Description
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territori...
EZZ Life Science Holdings Ltd. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 46.28M | 66.87M | 66.44M | 37.14M | 15.02M |
| Gross Profit | 25.77M | 49.72M | 50.95M | 27.20M | 7.51M |
| EBITDA | -6.12M | 11.10M | 10.38M | 5.09M | 1.90M |
| Net Income | -5.32M | 6.73M | 6.96M | 3.63M | 1.31M |
Balance Sheet | |||||
| Total Assets | 27.64M | 33.96M | 25.55M | 17.64M | 14.27M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 20.85M | 19.02M | 13.83M | 10.46M |
| Total Debt | 478.59K | 304.49K | 123.86K | 478.59K | 104.57K |
| Total Liabilities | 3.15M | 5.87M | 4.23M | 3.06M | 2.88M |
| Stockholders Equity | 24.49M | 28.09M | 21.32M | 14.58M | 11.39M |
Cash Flow | |||||
| Free Cash Flow | -8.79M | 4.09M | 5.73M | 3.91M | 1.89M |
| Operating Cash Flow | -8.76M | 4.35M | 6.14M | 4.01M | 1.90M |
| Investing Cash Flow | -652.32K | -546.93K | -441.17K | -101.78K | -13.18K |
| Financing Cash Flow | -1.26M | -2.17M | -582.45K | -761.72K | -277.36K |
EZZ Life Science Holdings Ltd. Technical Analysis
Negative
0.64
Price Trends
0.42
Negative
0.45
Negative
0.77
Negative
Market Momentum
-0.03
Negative
35.94
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.42, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 35.94 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.
EZZ Life Science Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$83.31M | 22.36 | 46.74% | ― | 29.68% | 1520.00% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$15.05M | -2.83 | -20.36% | 12.55% | -30.79% | -177.68% | |
44 Neutral | AU$2.85M | -2.65 | -101.34% | ― | ― | 64.58% | |
44 Neutral | AU$33.14M | -0.37 | -118.74% | ― | 499.47% | 31.20% | |
42 Neutral | AU$12.91M | -3.10 | -31.88% | ― | 5.85% | 45.13% |
* Healthcare Sector Average
AU:EZZ
EZZ Life Science Holdings Ltd.
0.32
-2.97
-90.28%
AU:ZLD
Zelira Therapeutics
0.50
0.15
42.86%
AU:IMC
Immuron Limited
0.04
-0.05
-56.52%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.13
-91.43%
AU:BIO
Biome Australia Ltd
0.36
-0.11
-22.58%
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Director Christine Chen Reduces Direct Shareholding
Sep 11, 2026
EZZ Life Science Holdings Limited has reported a change in the shareholding of director Christine Chen, who disposed of 30,900 ordinary shares in on-market trades conducted between 7 and 8 September 2026. Following these transactions, Chen’s...
EZZ Life Science Outlines 2026 Corporate Governance and Diversity Framework
Sep 1, 2026
EZZ Life Science Holdings has released its corporate governance statement for the year ended 30 June 2026, confirming broad adherence to the ASX Corporate Governance Council’s 4th edition principles and recommendations. The board has formali...
EZZ Life Science Releases Annual Report for Year Ended 30 June 2026
Aug 31, 2026
EZZ Life Science Holdings Ltd. has released its annual report for the year ended 30 June 2026, providing shareholders and stakeholders with a formal update on its financial and operational performance. The publication of the 2026 annual report mar...
EZZ Life Science Swings to Loss as Revenue Slides and Credit Provisions Rise
Aug 31, 2026
EZZ Life Science Holdings Limited reported a steep downturn for the year ended 30 June 2026, with revenues from ordinary activities falling 36.39% to $46.3 million and a swing from a prior-year profit to a net loss after tax of $5.3 million. Under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.